Pain Management in Palliative Care

Pharmacological Interventions

• The American Society of Clinical Oncology and the European Society for Medical Oncology recommend considering IV methylphenidate for rapid pain control in specific cancer pain management scenarios, as part of a comprehensive approach that includes proper opioid titration 1, 2
• IV methylphenidate may be considered as a second-line agent for treating opioid-induced sedation in palliative care settings, at a dose of 2 mg IV, but only after other methods to address sedation have been tried 1
• Methylphenidate is classified as a Schedule II controlled substance by the Drug Enforcement Administration due to its high abuse potential, highlighting the need for cautious use and monitoring 3

Adverse Effects and Contraindications

• Common adverse effects of methylphenidate include sleep disturbances, insomnia, dry mouth, sweating, irritability, decreased appetite, increased blood pressure, headaches, and stomach pain 4, 5, 6
• Stimulants, including methylphenidate, should be avoided in patients with uncontrolled hypertension, underlying coronary artery disease, and tachyarrhythmias, as recommended by the National Comprehensive Cancer Network and the American Heart Association 4, 6
• Nootropics should not be used in small children due to significant safety concerns, lack of FDA approval for pediatric use, and insufficient evidence supporting their efficacy and safety in this population 7, 5

Dosage and Administration

• Traditional stimulants, including methylphenidate, have a dose range of 5-30 mg/day, usually divided twice daily, and are primarily indicated for ADHD 4
• The following table compares the dosing of Immediate-Release Methylphenidate (Ritalin) and Extended-Release Methylphenidate (Concerta):

• When switching from immediate-release to extended-release methylphenidate, a conversion guide should be used, such as 10-15 mg/day IR → 18 mg Concerta once daily, with consideration of the duration of action, as recommended by the American Academy of Child and Adolescent Psychiatry 4, 3

Monitoring and Special Considerations

• Regular monitoring of blood pressure, heart rate, and assessment for side effects, including sleep disturbances and appetite changes, is recommended for patients taking stimulant medications, with consideration of treatment interruption if children are not growing or gaining weight as expected 4, 6
• Height and weight monitoring in children is also recommended due to the potential for growth suppression, a documented long-term concern with methylphenidate use in children, as reported in Pharmacology and Therapeutics 6
• Extended-release formulations, including Equasym XL/Metadate CD, improve medication adherence compared to immediate-release preparations that require multiple daily doses, according to the Pharmacology and Therapeutics guidelines 6